SANES

9.869

+0.23%↑

BBVA

19.145

-1.11%↓

ALV

385.7

+0.6%↑

MUV2

549.6

-1.4%↓

INGA

23.47

+0.41%↑

SANES

9.869

+0.23%↑

BBVA

19.145

-1.11%↓

ALV

385.7

+0.6%↑

MUV2

549.6

-1.4%↓

INGA

23.47

+0.41%↑

SANES

9.869

+0.23%↑

BBVA

19.145

-1.11%↓

ALV

385.7

+0.6%↑

MUV2

549.6

-1.4%↓

INGA

23.47

+0.41%↑

SANES

9.869

+0.23%↑

BBVA

19.145

-1.11%↓

ALV

385.7

+0.6%↑

MUV2

549.6

-1.4%↓

INGA

23.47

+0.41%↑

SANES

9.869

+0.23%↑

BBVA

19.145

-1.11%↓

ALV

385.7

+0.6%↑

MUV2

549.6

-1.4%↓

INGA

23.47

+0.41%↑

Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

203.3 -2.12

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

200.8

Max

207.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-23M

93M

Pardavimai

400K

745M

P/E

Sektoriaus vid.

76.495

29.392

Pelnas, tenkantis vienai akcijai

0.94

Pelno marža

12.43

Darbuotojai

10,134

EBITDA

-55M

201M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+12.82% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

321M

20B

Ankstesnė atidarymo kaina

205.42

Ankstesnė uždarymo kaina

203.3

Naujienos nuotaikos

By Acuity

20%

80%

30 / 528 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-16 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher, Aided by Fed Rate-Cut Prospects -- Market Talk

2025-12-16 23:38; UTC

Rinkos pokalbiai

Nikkei May Rise on Possible Bargain-Hunting Interest -- Market Talk

2025-12-16 22:35; UTC

Įsigijimai, susijungimai, perėmimai

Santos: Sale Delivered Cash, Reduced Future Decommissioning Exposure

2025-12-16 22:35; UTC

Įsigijimai, susijungimai, perėmimai

Santos Sold 43% Stake in Petrel Fields, 100% of Tern Fields to Eni Australia

2025-12-16 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Santos: A$40M Upfront Consideration, Up to A$20M in Contingent Payments

2025-12-16 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Santos Sold 43% Operated Interest in Mahalo JV to Comet Ridge

2025-12-16 22:32; UTC

Įsigijimai, susijungimai, perėmimai

Santos Divests Two Noncore Assets as Part of Portfolio Optimization

2025-12-16 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Westgold's Indicative Timetable Points to Early February Completion

2025-12-16 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Westgold: Divestment Aligns With Broader Corporate Strategy

2025-12-16 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Westgold: Deferred Payment Based on Performance Hurdles

2025-12-16 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Westgold Will Receive A$15M Cash, A$19.6M in Alicanto Shares

2025-12-16 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Westgold to Receive A$30M Deferred Payment in Cash or Shares

2025-12-16 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Westgold Divesting Noncore Operating Asset for A$64.6M

2025-12-16 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Westgold Agrees to Sell Mt Henry-Selene Project to Alicanto Minerals

2025-12-16 21:53; UTC

Uždarbis

Lennar Misses Earnings Estimates. The Stock Is Dropping. -- Barrons.com

2025-12-16 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-12-16 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- 2nd Update

2025-12-16 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- Update

2025-12-16 21:17; UTC

Įsigijimai, susijungimai, perėmimai

Worthington Enterprises to Buy LSI Group for About $205M >WOR

2025-12-16 21:16; UTC

Uždarbis

Worthington Enterprises 2Q Sales $327.5M >WOR

2025-12-16 21:16; UTC

Uždarbis

Worthington Enterprises 2Q Adj EPS 65c >WOR

2025-12-16 21:16; UTC

Uždarbis

Worthington Enterprises 2Q EPS 55c >WOR

2025-12-16 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Worthington Enterprises Agrees To Acquire Leading Metal Roof Components Manufacturer LSI Group >WOR

2025-12-16 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Ecolab Closes Acquisition Of Ovivo's Electronics Ultrapure Water Business >ECL

2025-12-16 20:54; UTC

Įsigijimai, susijungimai, perėmimai

Warner to Reject Paramount Offer As Soon As Wednesday, Sources Say -- WSJ

2025-12-16 20:54; UTC

Įsigijimai, susijungimai, perėmimai

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- WSJ

2025-12-16 20:54; UTC

Įsigijimai, susijungimai, perėmimai

Warner to Recommend Existing Netflix Deal, Sources Say -- WSJ

2025-12-16 20:44; UTC

Rinkos pokalbiai

Russia-Ukraine Peace Efforts Send Crude to Near 5-Year Low -- Market Talk

2025-12-16 20:04; UTC

Rinkos pokalbiai

U.S. Natural Gas Extends Weather-Driven Losing Streak -- Market Talk

2025-12-16 20:01; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

12.82% į viršų

12 mėnesių prognozė

Vidutinis 235 EUR  12.82%

Aukščiausias 260 EUR

Žemiausias 210 EUR

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

6

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

30 / 528 reitingas Finansų sektorius

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat